Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease.

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

A new study found that some medications could have the unintended benefit of reducing dementia risk, while others could increase the risk. A doctor comments on the findings.

Jaime Bortz, 39, is losing her memory to dementia. Her mom, now a full-time carer, is foreshadowing the burden many families ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...